The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Vasoactive Intestinal Peptide-Receptor Imaging for the Localization of Intestinal Adenocarcinomas and Endocrine Tumors
Abstract
BACKGROUND: Intestinal adenocarcinomas and various endocrine tumors express large numbers of high-affinity receptors for vasoactive intestinal peptide (VIP). We have evaluated the usefulness of scanning with VIP labeled with iodine-123 for tumor localization in patients with gastrointestinal tumors. METHODS: Radioiodinated VIP was purified by high-pressure liquid chromatography and administered as a single intravenous bolus injection (300 pmol [1 microgram]). Scanning with radiolabeled VIP was compared with computed tomography and scanning with somatostatin analogues in 79 patients with colorectal cancer, pancreatic carcinoma, gastric cancer, carcinoid tumor, or insulinoma. RESULTS: Visualization of gastrointestinal tumors and metastases was obtained with radiolabeled VIP. Binding of the labeled peptide by primary tumors and metastases was visible shortly after the injection and was still demonstrable at 24 hours. In patients with colorectal adenocarcinomas, primary or recurrent tumors were visualized in 10 of 10, liver metastases in 15 of 18, lung metastases in 2 of 3, and lymph-node metastases in 4 of 4. Primary pancreatic adenocarcinomas were visualized by imaging in 10 of 12 patients, and liver metastases were seen in 7 of 7. Primary or recurrent gastric adenocarcinomas were visualized in 5 of 5 patients, and liver metastases were seen in 2 of 2 patients. VIP scans were positive in 9 of 10 patients with carcinoid tumors and in 4 of 4 patients with insulinomas. Some tumors with positive VIP scans were also visualized with somatostatin analogues (4 of 17 colorectal adenocarcinomas, 8 of 9 carcinoids, and 2 of 2 insulinomas). In vitro binding studies confirmed the presence of VIP receptors on gastrointestinal tumors. CONCLUSIONS: Scanning with radiolabeled VIP can visualize intestinal tumors and metastases that express receptors for VIP.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Krenning, E. P., Kwekkeboom, D. J., Bakker, W. H., Breeman, W. A. P., Kooij, P. P. M., Oei, H. Y., van Hagen, M., Postema, P. T. E., de Jong, M., Reubi, J. C., et al. (1993) · European Journal of Nuclear Medicine · doi:10.1007/bf00181765 · Cited by 1,564
Islet cell tumor and a syndrome of refractory watery diarrhea and hypokalemia
Verner, J. V., & Morrison, A. B. (1958) · The American Journal of Medicine · doi:10.1016/0002-9343(58)90075-5 · Cited by 636
LOCALISATION OF ENDOCRINE-RELATED TUMOURS WITH RADIOIODINATED ANALOGUE OF SOMATOSTATIN
Krenning, E. P., Breeman, W. A. P., Kooij, P. P. M., Lameris, J. S., Bakker, W. H., Koper, J. W., Ausema, L., Reubi, J. C., & Lamberts, S. W. J. (1989) · The Lancet · doi:10.1016/s0140-6736(89)91258-0 · Cited by 625
Somatostatin-Receptor Imaging in the Localization of Endocrine Tumors
Lamberts, S. W. J., Barker, W. H., Reubi, J.-C., & Krenning, E. P. (1990) · New England Journal of Medicine · doi:10.1056/nejm199011013231805 · Cited by 532
Krenning, E. P., Bakker, W., Kooij, P. P. M., Breeman, W. A., Oei, H. Y., de Jong, M., Reubi, J. C., Visser, T. J., Bruns, C., & Kwekkeboom, D. J. (1992) · PubMed · Cited by 420
Schwartz, C. J., Kimberg, D. V., Sheerin, H. E., Field, M., & Said, S. I. (1974) · Journal of Clinical Investigation · doi:10.1172/jci107790 · Cited by 382
Said, S. I., Faloona, G. R., Harvey, S., Deon, H., & Ford, W. T. (1975) · New England Journal of Medicine · doi:10.1056/nejm197507242930401 · Cited by 335
Ottaway, C. A. (1984) · The Journal of experimental medicine · doi:10.1084/jem.160.4.1054 · Cited by 188
Vasoactive intestinal peptide and neuropeptide modulation of the immune response
O'Dorisio, M. S., Wood, C. L., & O'Dorisio, T. M. (1985) · The Journal of Immunology · doi:10.4049/jimmunol.135.2.792 · Cited by 167
A ticket to ride: peptide radiopharmaceuticals.
Fischman, A. J., Babich, J. W., & Strausś, H. W. (1993) · PubMed · Cited by 155
Cited by
The diagnosis and medical management of advanced neuroendocrine tumors.
Kaltsas, G. A., Besser, G. M., & Grossman, A. B. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0014 · Cited by 674
Imaging of Neuroendocrine Tumors
Heller, M. T., & Shah, A. B. (2011) · Radiologic Clinics of North America · doi:10.1016/j.rcl.2011.02.011 · Cited by 329
Metadata
- Authors
- Virgolini, I., Raderer, M., Kurtaran, A., Angelberger, P., Banyai, S., Yang, Q., Li, S., Banyai, M., Pidlich, J., Niederle, B., Scheithauer, W., & Valent, P.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1994-10-27
- Volume
- 331
- Issue
- 17
- Pages
- 1116-1121
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2334684541
- Cited by
- 257
- References
- 11
- FWCI
- 17.39
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Vasoactive Intestinal Peptide-Receptor Imaging for the Localization of Intestinal Adenocarcinomas and Endocrine Tumors. https://app.cochat.ai/papers/10.1056/nejm199410273311703
- The paper
- Virgolini, I., Raderer, M., Kurtaran, A., Angelberger, P., Banyai, S., Yang, Q., Li, S., Banyai, M., Pidlich, J., Niederle, B., Scheithauer, W., & Valent, P. (1994). Vasoactive Intestinal Peptide-Receptor Imaging for the Localization of Intestinal Adenocarcinomas and Endocrine Tumors. New England Journal of Medicine. https://doi.org/10.1056/nejm199410273311703
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
